# Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

> **NCT05433896** · PHASE1 · COMPLETED · sponsor: **Xspray Pharma AB** · enrollment: 17 (actual)

## Conditions studied

- Pharmacokinetics
- Drug Interactions

## Interventions

- **DRUG:** Dasatinib ASD
- **DRUG:** Omeprazole 40 MG

## Key facts

- **NCT ID:** NCT05433896
- **Lead sponsor:** Xspray Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-01
- **Primary completion:** 2020-12-19
- **Final completion:** 2020-12-19
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05433896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05433896, "Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05433896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*